Performant Healthcare, Inc.
PHLT News Today: Stay Updated with the Latest Performant Healthcare, Inc. News in Real Time
Find PHLT news now at Meyka AI. Stay informed with the latest Performant Healthcare, Inc. stocks updates, including price news, market analysis, and expert insights.
^GSPC Today, February 23: Spanberger SOTU Reply Puts Health Costs in Focus
Abigail Spanberger SOTU ponse puts US healthcare costs in focus. What it could mean for ^GSPC levels, risk sentiment, and UK portfolios, with key technicals and 2026 midterms context.
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch
Pre-market: ABT.SW stock falls 13.50% to CHF86.50 on 24 Feb 2026; oversold technicals and Meyka AI projects CHF100.56 target
VisionSys AI (0T8B.F XETRA) -37.50% pre-market 24 Feb 2026: liquidity
Pre-market update on 0T8B.F stock: down 37.50% to €0.05 on XETRA with low liquidity and weak fundamentals
CNQ.TO Canadian Natural (TSX) C$58.02 close 23 Feb 2026: Most active, see Meyka
CNQ.TO stock closed C$58.02 on 23 Feb 2026 with 13.47M shares; technicals overbought and Meyka forecast shows downside
Rob Jetten on February 24: Child‑Benefit Shakeup, SCP Flags Fiscal Risks
Rob Jetten’s child benefit reform draws CPB and SCP warnings. What it means for Swiss investors with Dutch exposure: demand, insurers, childcare, and fiscal trade-offs.
9888.HK Baidu (HKSE) pre-market 24 Feb 2026: earnings ahead, figures to watch
Pre-market earnings spotlight for 9888.HK stock on 24 Feb 2026 with price, Meyka forecast and targets
TD, BMO, Scotiabank Maintain Buy/Outperform for Sienna Senior Living (LWSCF) Feb 2026
LWSCF analyst rating update: three firms maintained Buy/Outperform and raised price targets in Feb 2026
PRE MARKET: LTIM.NS (LTIMindtree) NSE Feb 2026 $100.00m deal: model +28.09%
Pre-market analysis of LTIM.NS stock on 24 Feb 2026, deal update, valuation and Meyka AI forecast projecting +28.09% yearly upside
February 24: Takaichi Cabinet 2.0 Backs Drug Investment, Biosimilar Parity
Takaichi Cabinet 2.0 backs public-private drug R&D and extends Japan drug pricing reform 2026 to biologics via the G1 rule, moving originator prices toward biosimilar parity. What it means for Japan’s